Last reviewed · How we verify

Bridge therapy

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta · FDA-approved active Small molecule

Bridge therapy refers to a transitional treatment strategy that maintains disease control while switching between long-term therapies.

Bridge therapy refers to a transitional treatment strategy that maintains disease control while switching between long-term therapies. Used for Transitional therapy during treatment switches in neurological conditions.

At a glance

Generic nameBridge therapy
SponsorFondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

Bridge therapy is a clinical approach rather than a specific drug, typically used in neurology and other specialties to provide continuous therapeutic benefit during transitions between primary treatments. It serves as an interim intervention to prevent disease progression or symptom exacerbation when discontinuing one therapy before initiating another.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: